BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su T, Kao J. Improving clinical outcomes of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:141-54. [DOI: 10.1586/17474124.2015.960398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Su TH, Kao JH. Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2017;37:310-1. [PMID: 28070982 DOI: 10.1111/liv.13315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Xing T, Xu H, Cao L, Ye M. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One 2017;12:e0169444. [PMID: 28107377 DOI: 10.1371/journal.pone.0169444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
3 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
4 Su TH, Liu CJ. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver 2017;11:590-603. [PMID: 28494575 DOI: 10.5009/gnl16215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Su TH, Shiau CW, Jao P, Yang NJ, Tai WT, Liu CJ, Tseng TC, Yang HC, Liu CH, Huang KW, Hu TC, Huang YJ, Wu YM, Chen LJ, Chen PJ, Chen DS, Chen KF, Kao JH. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep 2017;7:1728. [PMID: 28496142 DOI: 10.1038/s41598-017-01572-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Lin CL, Kao JH. Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence. Gastroenterol Clin North Am. 2020;49:201-214. [PMID: 32389359 DOI: 10.1016/j.gtc.2020.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Reference Citation Analysis]
8 Schütte K, Balbisi F, Malfertheiner P. Prevention of Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:37-43. [PMID: 27722155 DOI: 10.1159/000446680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kao JH. Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2015;29:907-17. [PMID: 26651252 DOI: 10.1016/j.bpg.2015.09.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
10 Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, Schwabe C, Dunbar PR. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71:900-907. [PMID: 31306680 DOI: 10.1016/j.jhep.2019.06.028] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 25.3] [Reference Citation Analysis]
11 Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755-1764. [PMID: 27634134 DOI: 10.1111/liv.13253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
12 Mak LY, Huang Q, Wong DK, Stamm L, Cheung KS, Ko KL, Yan R, Ouyang L, Fung J, Seto WK, Yuen MF. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol 2021;56:479-88. [PMID: 33772643 DOI: 10.1007/s00535-021-01780-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tseng TC, Kao JH. Elimination of Hepatitis B: Is It a Mission Possible? BMC Med 2017;15:53. [PMID: 28292309 DOI: 10.1186/s12916-017-0820-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
14 Wei L, Kao JH. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. Curr Med Res Opin 2017;33:495-504. [PMID: 27882776 DOI: 10.1080/03007995.2016.1264932] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kao J. Hepatitis B: From control to cure. Journal of the Formosan Medical Association 2018;117:868-70. [DOI: 10.1016/j.jfma.2018.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
16 Yang HC, Kao JH. Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy? Nat Rev Gastroenterol Hepatol. 2015;12:129-131. [PMID: 25623202 DOI: 10.1038/nrgastro.2015.8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
17 Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis 2017;216:S750-6. [PMID: 29156048 DOI: 10.1093/infdis/jix382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
18 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Mak LY, Ko M, To E, Wong DK, Ma JH, Hui TL, Seto WK, Fung J, Lai CL, Yuen MF. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol 2019;34:1817-23. [PMID: 30786068 DOI: 10.1111/jgh.14637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]